Madelaine M Wohlreich

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint Answers to the most common questions about the hepatic safety profile of duloxetine
    Madelaine M Wohlreich
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Postgrad Med 120:111-8. 2008
  2. pmc Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study
    Madelaine M Wohlreich
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana, USA
    Prim Care Companion J Clin Psychiatry 9:271-9. 2007
  3. ncbi request reprint Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine
    Madelaine M Wohlreich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Ann Clin Psychiatry 17:259-68. 2005
  4. ncbi request reprint An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches
    Madelaine M Wohlreich
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 25:552-60. 2005
  5. doi request reprint Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis
    Madelaine M Wohlreich
    correspondence and M D, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4103, Indianapolis, IN 46285, USA
    Psychosomatics 50:402-12. 2009
  6. pmc Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 222 Piedmont Avenue, Suite 8200, Cincinnati, OH 45219, USA
    Arthritis Res Ther 13:R86. 2011
  7. pmc Effect of duloxetine in patients with fibromyalgia: tiredness subgroups
    Laurence A Bradley
    Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama 35294, USA
    Arthritis Res Ther 12:R141. 2010
  8. doi request reprint The effect of duloxetine treatment on cognition in patients with fibromyalgia
    Richard Mohs
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Psychosom Med 74:628-34. 2012
  9. ncbi request reprint Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range
    Craig H Mallinckrodt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Psychiatr Res 40:337-48. 2006
  10. pmc The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials
    Craig H Mallinckrodt
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    BMC Psychiatry 4:26. 2004

Detail Information

Publications18

  1. doi request reprint Answers to the most common questions about the hepatic safety profile of duloxetine
    Madelaine M Wohlreich
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Postgrad Med 120:111-8. 2008
    ..Therefore, it does not warrant hepatic enzyme monitoring. As with any medication, physicians should follow prescribing guidelines and educate patients on the risks and benefits of duloxetine...
  2. pmc Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study
    Madelaine M Wohlreich
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana, USA
    Prim Care Companion J Clin Psychiatry 9:271-9. 2007
    ..Clinical Trials Registration: ClinicalTrials.gov identifier NCT00479726...
  3. ncbi request reprint Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine
    Madelaine M Wohlreich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Ann Clin Psychiatry 17:259-68. 2005
    ..We examined the efficacy and tolerability associated with a switch from a selective serotonin reuptake inhibitor (SSRI) or venlafaxine to duloxetine...
  4. ncbi request reprint An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches
    Madelaine M Wohlreich
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 25:552-60. 2005
    ..Immediate switching from a selective serotonin reuptake inhibitor or venlafaxine to duloxetine (60 mg QD) was well tolerated...
  5. doi request reprint Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis
    Madelaine M Wohlreich
    correspondence and M D, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4103, Indianapolis, IN 46285, USA
    Psychosomatics 50:402-12. 2009
    ....
  6. pmc Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 222 Piedmont Avenue, Suite 8200, Cincinnati, OH 45219, USA
    Arthritis Res Ther 13:R86. 2011
    ..Fatigue was assessed as a secondary objective in a 2-phase, 24-week study in outpatients with American College of Rheumatology-defined fibromyalgia...
  7. pmc Effect of duloxetine in patients with fibromyalgia: tiredness subgroups
    Laurence A Bradley
    Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama 35294, USA
    Arthritis Res Ther 12:R141. 2010
    ..This study tested the hypothesis that baseline ratings of fatigue/tiredness would be negatively associated with the efficacy of duloxetine on measures of pain and functional ability in patients with fibromyalgia...
  8. doi request reprint The effect of duloxetine treatment on cognition in patients with fibromyalgia
    Richard Mohs
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Psychosom Med 74:628-34. 2012
    ..To determine the effect of duloxetine treatment on cognition in patients with fibromyalgia...
  9. ncbi request reprint Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range
    Craig H Mallinckrodt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Psychiatr Res 40:337-48. 2006
    ..This analysis focuses on efficacy and safety data obtained from studies of duloxetine for the treatment of major depressive disorder (MDD) within the approved dose range of 40-60 mg/day...
  10. pmc The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials
    Craig H Mallinckrodt
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    BMC Psychiatry 4:26. 2004
    ..We compared results from MMRM and LOCF_ANCOVA analyses across eight clinical trials of duloxetine in order to investigate how the choice of primary analysis may influence interpretations of efficacy...
  11. ncbi request reprint A comparison of initial duloxetine dosing strategies in patients with major depressive disorder
    Virgil G Whitmyer
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 68:1921-30. 2007
    ..To compare the effects of starting doses of duloxetine taken with or without food on tolerability and efficacy in patients with major depressive disorder (MDD)...
  12. pmc Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features
    Craig H Mallinckrodt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    BMC Psychiatry 5:1. 2005
    ..Pooled data from double-blind, placebo-controlled studies were utilized to compare the efficacy of duloxetine in depressed patients with and without melancholic features...
  13. ncbi request reprint Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation
    Madelaine M Wohlreich
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
    Depress Anxiety 24:41-52. 2007
    ..Time course profiles of body weight and heart rate showed modest increases during 2 years of treatment [ClinicalTrials.gov number, NC T000 42575]...
  14. doi request reprint Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine
    Lauren B Marangell
    Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Pain 152:31-7. 2011
    ..Hence, both direct and indirect analgesic and antidepressant properties appear to be relevant for the treatment of these comorbid patients with duloxetine...
  15. pmc Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Ohio Department of Anesthesiology, Chronic Pain and Fatigue Research Center, University of Michigan Medical Center, Ann Arbor and Eli Lilly and Company and or one of its subsidiaries, Indianapolis, Indiana
    Prim Care Companion J Clin Psychiatry 11:237-44. 2009
    ..To investigate the efficacy of duloxetine in the treatment of pain and improvement in functional impairment and quality of life in patients with fibromyalgia from a pooled analysis of 4 placebo-controlled, double-blind, randomized trials...
  16. doi request reprint Comparison of safety outcomes among Caucasian, Hispanic, Black, and Asian patients in duloxetine studies of chronic painful conditions
    Paula J Gaynor
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Curr Med Res Opin 29:549-60. 2013
    ..This post-hoc analysis was conducted to investigate if safety outcomes differed among race/ethnic subgroups of patients treated with duloxetine for chronic painful conditions...
  17. doi request reprint The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective
    Ronald C Wielage
    Medical Decision Modeling Inc, Indianapolis, IN 46268, USA
    Value Health 16:334-44. 2013
    ..To assess the cost-effectiveness of duloxetine in the treatment of chronic low back pain (CLBP) from a US private payer perspective...